First-in-human trials appropriately begin at very low doses to mitigate risk, often below the sensitivity limits of flow cytometry and bulk molecular assays. ​

CB-Scout resolves pharmacodynamic signals at these starting doses—commonly used for CAR-T, CAR-NK, and first-in-class cellular therapies—supporting informed dose-escalation decisions and early go/no-go assessments with direct biological evidence.​

When evaluating related products—such as standard CAR-T versus armored CAR-T constructs, or therapies augmented with cytokine support (e.g., IL-15)—early biological differences may be subtle and missed by clinical endpoints alone. ​

CB-Scout enables side-by-side in-vivo comparison of persistence, expansion, and phenotype, revealing functional differentiation before outcome measures diverge.​

Cell therapies for autoimmune disease and immune tolerance, including regulatory T-cell–based approaches, are intentionally administered at very small doses to avoid immune suppression. ​

CB-Scout enables sensitive in-vivo monitoring of rare regulatory cell populations, supporting mechanism-of-action and durability assessments in settings where conventional assays lack sufficient resolution.

Even small numbers of therapeutic cells in sensitive compartments—such as CSF —can have significant safety implications. ​

CB-Scout detects rare off-target localization of therapeutic cells, including CAR-T and CAR-NK products, providing early insight into biodistribution and safety beyond what peripheral blood or bulk tissue assays can resolve.​